Evaxion expands AI-Immunology™ platform into autoimmune diseases
EVAXCOPENHAGEN, Denmark, January 13, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will expand the use of its proprietary AI-Immunology™ platform to also discover and develop new treatments for autoimmune diseases. Thus, Evaxion will in the future work within cancers, infectious and autoimmune diseases as its core disease areas.
Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01
EVAXCOPENHAGEN, Denmark, November 7, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new data exploring immune responses following treatment with AI-designed personalized cancer vaccine EVX-01. The data was presented today in a poster session at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting taking place in National Harbor, Maryland.
Evaxion to present at several conferences during the second half of 2025
EVAXCOPENHAGEN, Denmark, August 27, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting data and company updates at numerous scientific and investor conferences throughout the second half of 2025.
Evaxion announces business update and second quarter 2025 financial results
EVAXCOPENHAGEN, Denmark, August 14, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces second quarter 2025 financial results.
Evaxion Awarded Gates Foundation Grant To Advance AI-Powered Vaccine Design Targeting Global Polio Eradication, Using Its AI-Immunology Platform To Develop Novel Antigen Constructs Amid Ongoing Risk Of Global Resurgence; No Financial Terms Disclosed
EVAXA Look at Evaxion Biotech's Upcoming Earnings Report
EVAXEvaxion Annoucnes It Has Dosed First Patient In Extension Of Phase 2 Trial Exploring The Full Potential Of AI-Designed Personalized Cancer Vaccine Evx-01
EVAXWatching Evaxion Biotech; Zacks Small-Cap Research Gives Stock $19.75 Price Valuation
EVAXEvaxion Biotech Announces Data Underscoring Ability Of Cancer Vaccine EVX-01
EVAXHC Wainwright & Co. Reiterates Buy on Evaxion Biotech, Maintains $14 Price Target
EVAXEvaxion Biotech Q4 EPS $(0.07) Beats $(0.15) Estimate, Sales $122.00K Miss $1.66M Estimate
EVAXEarnings Scheduled For April 1, 2025
EVAXEvaxion To Present New Phase 2 Data For AI-Designed Personalized Cancer Vaccine EVX-01 At AACR 2025 Annual Meeting
EVAXHC Wainwright & Co. Reiterates Buy on Evaxion Biotech, Maintains $14 Price Target
EVAXEvaxion Completes Dosing In Phase 2 Trial With Personalized Cancer Vaccine EVX-01; Trial Remains On Track For Completion And Data Readout In The Second Half Of 2025
EVAXTrading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
EVAXTrading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
EVAXEvaxion Announces Extension To January 14, 2025, Of Plan To Implement ADS Ratio Change From The Current One 1 ADS Representing 10 Ordinary Share To A New ADS Ratio Of 1 ADS Representing 50 Ordinary Shares
EVAXHC Wainwright & Co. Reiterates Buy on Evaxion Biotech, Maintains $14 Price Target
EVAXEvaxion Biotech Q3 2024 GAAP EPS $(0.04) Beats $(0.31) Estimate, Sales $3.017M Beat $123.333K Estimate
EVAX